ACAD
Acadia Pharmaceuticals Inc Health Care Pharmaceutical Preparations Russell 3000
$20.59Close
$3.5BMarket cap
$18.62 – $30.5752-week range
Nov 4, 2026Next report · after the close
Highlights
Strengths
- Tight base near its pivot pullbacks 41% → 5%; 0.1% above its $20.57 pivot
Cautions
- Not in an uptrend 1 of 8 trend conditions
- Lagging the market RS 21 · weaker than 79% of stocks over 12 months
- Far from its high 33% below its 52-week high
- Distribution down-day volume 1.6× up-day volume over 50 sessions
- Results soon Nov 4, 2026, in 3 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
33%
1wk
up 4.4%
price change
1mo
up 2.2%
price change
12-month return
down 9%
market up 11% ·
its own down 19%
F-score
6 / 9
Mixed
Altman Z
6.13
Low risk
P/E
9.0×
price / earnings
PEG
0.13
P/E / EPS growth
P/B
2.9×
price / book
Earnings yield
up 3.1%
EBIT / enterprise value
Cheaper than
50%
of the market · around average
Revenue growth
up 12%
year on year
EPS growth
up 15%
latest quarter · +97 pts
Sales growth
up 16%
latest quarter · +7 pts
ROE
up 40%
return on equity
Free cash margin
up 10%
$105.1M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
-1.7×
net cash
Interest cover
—EBIT / interest
Piotroski tests
- profits not fully backed by cash
- issued more shares
- assets working less efficiently
- profitable on its assets
- generating cash from operations
- profitability improving
- reduced long-term debt
- short-term liquidity improved
- gross margin widened
Trade setup
ATR%
3.3%
$0.67 a day · 2×ATR $19.25
RS
21 / 99
vs the universe
Trend
1 / 8
trend template
Relative volume
0.6×
vs 50-day average
Up/down volume
0.63
50 sessions
Implied move
—
no option chain · report Nov 4, 2026
Contractions
2
41% → 5%
Pivot
$20.57
0.1% above
Volume dry-up
0.8×
10 vs 50 sessions
Trend template · 1 of 8
- 150-day average above the 200-day: passes
Screen verdict
Did not qualify for any screen.
Warning signs
- Shareholders diluted The share count rose 2.2% over the year, from 167m to 170m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
- Profit not backed by cash Reported profit of $391.0M came with $109.8M of operating cash flow. Profit that cash does not follow is the classic signature of aggressive accounting.
Last reported
Aug 4, 2026
Last shock
Sep 24, 2026-13% in one session3.9× volumeon an SEC filing-7% since
Financials
- Gross 92%
- Net 36%
- Free cash 10%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $441.8M | $484.1M | $517.2M | $726.4M | $957.8M | $1.1B |
| Gross margin | 98% | 98% | 98% | 94% | 91% | 92% |
| Operating income | -$286.6M | -$170.4M | -$223.6M | -$73.4M | $230.8M | $104.8M |
| Net income | -$281.6M | -$168.0M | -$214.0M | -$61.0M | $226.0M | $391.0M |
| Net margin | -64% | -35% | -41% | -8% | 24% | 36% |
| Earnings per share | -$1,789.76 | -$1,046.77 | -$1.32 | -$0.37 | $1.36 | $2.30 |
| Free cash flow | -$143.8M | -$126.8M | -$114.0M | $16.7M | $157.2M | $105.1M |
| Free cash margin | -33% | -26% | -22% | 2% | 16% | 10% |
| Cash | $326.0M | $147.4M | $114.8M | $188.7M | $319.6M | $177.7M |
| Shareholders' equity | $627.0M | $540.9M | $400.4M | $431.8M | $732.8M | $1.2B |
| Shares outstanding | 159.64m | 161.01m | 162.06m | 164.65m | 166.71m | 170.31m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 5, 2026 | Quarterly ↗ | Jun 30, 2026 | 36d |
| May 7, 2026 | Quarterly ↗ | Mar 31, 2026 | 37d |
| Feb 26, 2026 | Annual ↗ | Dec 31, 2025 | 57d |
| Nov 6, 2025 | Quarterly ↗ | Sep 30, 2025 | 37d |
| Aug 7, 2025 | Quarterly ↗ | Jun 30, 2025 | 38d |
| May 8, 2025 | Quarterly ↗ | Mar 31, 2025 | 38d |
| Feb 27, 2025 | Annual ↗ | Dec 31, 2024 | 58d |
| Nov 7, 2024 | Quarterly ↗ | Sep 30, 2024 | 38d |
| Aug 7, 2024 | Quarterly ↗ | Jun 30, 2024 | 38d |
| May 9, 2024 | Quarterly ↗ | Mar 31, 2024 | 39d |
| Feb 28, 2024 | Annual ↗ | Dec 31, 2023 | 59d |
| Nov 3, 2023 | Quarterly ↗ | Sep 30, 2023 | 34d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 23, 2026 | Director or officer change ↗ |
| Sep 24, 2026 | Regulation FD · Other events ↗ |
| Sep 11, 2026 | Other events ↗ |
| Aug 4, 2026 | Results ↗ |
| May 29, 2026 | Director or officer change · Shareholder vote ↗ |
| May 6, 2026 | Results ↗ |
| May 1, 2026 | Director or officer change · Regulation FD ↗ |
| Mar 5, 2026 | Director or officer change ↗ |
| Feb 25, 2026 | Results ↗ |
| Jan 13, 2026 | Results · Regulation FD ↗ |
| Nov 5, 2025 | Results ↗ |
| Nov 3, 2025 | Director or officer change ↗ |